The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations.
- 31 July 2001
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 55 (6), 295-300
- https://doi.org/10.1016/s0753-3322(01)00074-9
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Effect of HAART on Health Status and Hospital Costs of Severe HIV-Infected Patients: A Modeling ApproachHIV Research & Clinical Practice, 2001
- Rate of HIV-1 RNA rebound upon stopping antiretroviral therapyAIDS, 1999
- Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostaticsBiomedicine & Pharmacotherapy, 1998
- Cobalamin Inhibition of HIV-1 Integrase and Integration of HIV-1 DNA into Cellular DNABiochemical and Biophysical Research Communications, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. Italian Zidovudine Evaluation GroupPublished by American Medical Association (AMA) ,1992
- DNA topoisomerases as potential targets of antiviral actionPharmacology & Therapeutics, 1989
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989
- Retroviral DNA integration: Structure of an integration intermediateCell, 1988
- ACRIFLAVINE AS A URINARY ANTISEPTICThe Lancet, 1936